aTyr Pharma, which is developing restorative protein therapeutics for rare muscular dystrophies, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, aTyr Pharma would command a fully diluted market value of $333 million.
aTyr Pharma, which was founded in 2005, plans to list on the NASDAQ under the symbol LIFE. J.P. Morgan and Citi are the joint bookrunners on the deal. It is expected to price during the week of May 4, 2015.
